[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-460038-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-460038-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","correction-impact-of-chemoradiotherapy-for-bladder-cancer-on-pre-existing-hydronephrosis-and-development-of-new-hydronephrosis","Correction - Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis","","Correction notice for a Radiation Oncology article addressing a typesetting error in figure captions. Portions of captions from Figs. 1 and 5 were inadvertently included in the main text. The corrected caption text clarifies analyses for nephron-sparing and bladder-sparing perspectives in patients with pre-existing hydronephrosis, including criteria using eGFR thresholds and kidney atrophy. It also specifies counseling and management guidance for chemoradiotherapy, including the role of DMSA scan, relative hydronephrotic kidney function thresholds, and when drainage or cystectomy should be recommended.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/correction-impact-of-chemoradiotherapy-for-bladder-cancer-on-pre-existing-hydronephrosis-and-development-of-new-hydronephrosis/460038/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/correction-impact-of-chemoradiotherapy-for-bladder-cancer-on-pre-existing-hydronephrosis-and-development-of-new-hydronephrosis/460038.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What was corrected in the article?","Question",{"text":62,"@type":63},"Caption text from Figs. 1 and 5 was mistakenly captured as part of the main text due to a typesetting mistake. The notice provides the corrected caption wording.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What does the corrected Fig. 1 caption describe?",{"text":67,"@type":63},"It describes how patients with pre-existing hydronephrosis are analyzed for nephron-sparing and bladder-sparing perspectives, including components and thresholds related to eGFR and kidney atrophy.",{"name":69,"@type":60,"acceptedAnswer":70},"How should patients be counseled according to the corrected Fig. 5 caption?",{"text":71,"@type":63},"Patients should be counseled on both bladder-sparing and nephron-sparing approaches; when CRT is considered, a DMSA scan is used to assess relative renal function, guiding whether CRT can proceed without drainage and when drainage or cystectomy may be needed.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},460038,1790757566,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":96,"preview_page_count":4},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Remmelink etal. Radiation Oncology (2026) 21:8  \n[https://doi.org/10.1186/s13014-025-02729-1](https://doi.org/10.1186/s13014-025-02729-1)  \nRadiation Oncology  \nCORRECTION Open Access  \nCorrection: Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis  \nMarinka J. Remmelink 1,2*, Nader el Awadly3, Berber Arbeel-Weening4, Sven Nadorp5, Maicle R. Leter6, Jorg R. Oddens 1,2, Katharina Brück7,8, Jakko A. Nieuwenhuijzen2,9 and Adriaan D. Bins3  \nCorrection to: Radiation Oncology (2025) 20:104  \n[https://doi.org/10.1186/s13014-025-02678-9](https://doi.org/10.1186/s13014-025-02678-9)  \n[In this article](In this article), part of the captions of Figs. 1 and 5 were captured as part of the main text of the article, due to a typesetting mistake.  \nThe following text should have been captured as part of the caption of Fig. 1, instead of as part of the main text:  \nAll patients with pre-existing hydronephrosis are analyzed for the nephron-sparing and for the bladder-sparing perspectives. Drainage, cystectomy and local MIBC recurrence at any location in the bladder are components of both COs. Additional components in the nephronsparing CO are (1) a decrease in eGFR of ≥ 1 category and (2) the development of an atrophic kidney. The additional component of the bladder-sparing perspective CO is an  \neGFR \u003C 30 ml/min/1.73 m2. If any component of the perspective’s CO occurred in a patient, CRT was regarded asan unpreferred treatment choice in that patient.  \nThe following text should have been captured as part of the caption of Fig. 5, instead of as part of the main text:  \nPatients should be counselled on both bladder-sparing and nephron-sparing treatment approaches. In cases where the patient expresses a preference for chemoradiotherapy (CRT) and meets the necessary criteria, adimercaptosuccinic acid (DMSA) scan should be conducted to evaluate the relative function of the hydronephrotic kidney. In cases where the relative function is less than 10%, CRT can be performed without the need for drainage. However, it is imperative to discuss the risks of complications, such as infection, with the patient. In instances where the relative function is 10% or greater,  \nThe original article can be found online at [https://doi.org/10.1186/s1](https://doi.org/10.1186/s1)[ ](https://doi.org/10.1186/s1)[3014-025-02678-9](3014-025-02678-9.)[.](3014-025-02678-9.)  \n*Correspondence:  \nMarinka J. Remmelink  \n[m.j. remmelink@amsterdamumc.nl](m.j. remmelink@amsterdamumc.nl)  \n1VUmc Department of Urology, Amsterdam University Medical Center, University of Amsterdam, Boelelaan 1117, Amsterdam  \n1081HV, The Netherlands  \n2Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands  \n3Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands 4Flevoziekenhuis, Department of Urology, Almere, the Netherlands 5Amstel land Hospital, Department of Urology, Amstelveen, the Netherlands  \n6Dijklander Hospital, Department of Urology, Hoorn, the Netherlands 7Department of Radiation Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands  \n8Cancer Center Amsterdam, Therapy and Supportive Care, Amsterdam, The Netherlands  \n9Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other thir","cbCaicP3Bdf6x5X1","https://ap.wps.com/l/cbCaicP3Bdf6x5X1","pdf",594615,"English","# Correction notice\n## Figure caption typesetting errors\n## Corrected caption content for Fig. 1\n## Corrected caption content for Fig. 5\n## Publisher and licensing notes","[{\"question\":\"What was corrected in the article?\",\"answer\":\"Caption text from Figs. 1 and 5 was mistakenly captured as part of the main text due to a typesetting mistake. The notice provides the corrected caption wording.\"},{\"question\":\"What does the corrected Fig. 1 caption describe?\",\"answer\":\"It describes how patients with pre-existing hydronephrosis are analyzed for nephron-sparing and bladder-sparing perspectives, including components and thresholds related to eGFR and kidney atrophy.\"},{\"question\":\"How should patients be counseled according to the corrected Fig. 5 caption?\",\"answer\":\"Patients should be counseled on both bladder-sparing and nephron-sparing approaches; when CRT is considered, a DMSA scan is used to assess relative renal function, guiding whether CRT can proceed without drainage and when drainage or cystectomy may be needed.\"}]","Correction - Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis | PDF"]